Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by BackTable LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BackTable LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Ep. 247 Keynote 689: Implementation & Multidisciplinary Care for Immunotherapy in Head & Neck Cancer with Dr. Adam Luginbuhl, Dr. Jennifer Johnson, Dr. Mihir Patel and Dr. Siddharth Sheth

48:38
 
Share
 

Manage episode 518842964 series 3569300
Content provided by BackTable LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BackTable LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

When treating head and neck cancer, how can you tell the difference between true disease progression and pseudoprogression? In this episode of the BackTable Podcast, we discuss the practical implementation of the KEYNOTE-689 trial published in the New England Journal of Medicine, which demonstrated the benefit of adding neoadjuvant and adjuvant immunotherapy to standard head and neck cancer care. Our tumor board panel includes Dr. Mihir Patel, a head and neck surgeon from UNC Chapel Hill, Dr. Siddharth Sheth, a head and neck medical oncologist from UNC, Dr. Jennifer Johnson, a professor of medical oncology and otolaryngology at Sidney Kimmel Comprehensive Cancer Center, and Dr. Adam Luginbuhl, a head and neck surgical oncologist at Thomas Jefferson University.

---

SYNPOSIS

The doctors address the trial's practical implications, patient selection, case management, dealing with tumor progression, and the integration of multidisciplinary care. They also emphasize the importance of communication, real-world application of trial protocols, and the potential benefits and challenges of such therapies.

---

TIMESTAMPS

00:00 - Introduction
03:18 - Discussing the New Indication for Immunotherapy
11:42 - Challenges and Practical Implementation
22:48 - Managing Tumor Progression: A Case Study
28:07 - Exploring Treatment Options: Surgery vs. Chemotherapy
36:46 - Operational Challenges and Future Directions
43:58 - Concluding Thoughts and Future Directions

---

RESOURCES

Keynote 689
https://www.nejm.org/doi/full/10.1056/NEJMoa2415434

  continue reading

249 episodes

Artwork
iconShare
 
Manage episode 518842964 series 3569300
Content provided by BackTable LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BackTable LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

When treating head and neck cancer, how can you tell the difference between true disease progression and pseudoprogression? In this episode of the BackTable Podcast, we discuss the practical implementation of the KEYNOTE-689 trial published in the New England Journal of Medicine, which demonstrated the benefit of adding neoadjuvant and adjuvant immunotherapy to standard head and neck cancer care. Our tumor board panel includes Dr. Mihir Patel, a head and neck surgeon from UNC Chapel Hill, Dr. Siddharth Sheth, a head and neck medical oncologist from UNC, Dr. Jennifer Johnson, a professor of medical oncology and otolaryngology at Sidney Kimmel Comprehensive Cancer Center, and Dr. Adam Luginbuhl, a head and neck surgical oncologist at Thomas Jefferson University.

---

SYNPOSIS

The doctors address the trial's practical implications, patient selection, case management, dealing with tumor progression, and the integration of multidisciplinary care. They also emphasize the importance of communication, real-world application of trial protocols, and the potential benefits and challenges of such therapies.

---

TIMESTAMPS

00:00 - Introduction
03:18 - Discussing the New Indication for Immunotherapy
11:42 - Challenges and Practical Implementation
22:48 - Managing Tumor Progression: A Case Study
28:07 - Exploring Treatment Options: Surgery vs. Chemotherapy
36:46 - Operational Challenges and Future Directions
43:58 - Concluding Thoughts and Future Directions

---

RESOURCES

Keynote 689
https://www.nejm.org/doi/full/10.1056/NEJMoa2415434

  continue reading

249 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play